跳到正文
原文
PharmaTimes· John Pinching·· 2026-10-19精选AI 评分67

欧盟CHMP积极支持 Libtayo (cemiplimab) 替代剂量方案

Libtayo dosing backed by CHMP

AI 导读

欧盟CHMP已对 Libtayo (cemiplimab) 替代剂量方案发出积极意见,建议将给药频率从每3周一次调整为前12周给药后每6周一次。该推荐涵盖所有已获批适应症,支持700mg 每6周给药或350mg每3周给药,且350mg剂量输注时间可缩短至15至30分钟。Regeneron 表示该建议基于药代动力学及临床数据。欧盟委员会预计将在未来数月内作出最终决定。

推荐理由

欧盟CHMP对Libtayo剂量调整发出积极意见,明确建议方案细节及EMA审批背景。

正文 · 原文

The CHMP has issued a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved indications.

The opinion supports reducing dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. It also recommends an optional reduction of infusion time for the 350 mg dose to 15 to 30 minutes, provided the first dose over 30 minutes was well tolerated.

A spokesperson for Regeneron said: “The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications.”

They added: “The positive CHMP opinion is supported by comprehensive pharmacokinetic and pharmacodynamic modeling and simulation data, integrated with clinical safety and efficacy data from Libtayo’s clinical development program.”

The recommendation supports a higher-dose 700 mg infusion every six weeks following an initial 12-week regimen of 350 mg every three weeks.

It also allows a shorter infusion option for patients continuing on the 350 mg schedule. The European Commission is expected to make a final decision in the coming months, which would enable the updated regimen to be applied across all six approved indications.

The 700 mg six-week option is already approved in the US for use after 12 weeks as an adjuvant treatment for adults with cutaneous squamous cell carcinoma at high risk of recurrence. Across other indications, the existing 350 mg three-week regimen remains in place.

Libtayo is a fully human monoclonal antibody targeting PD-1 and has been approved in more than 30 countries for certain adult patients with advanced BCC, CSCC, NSCLC and cervical cancer.

It is also being investigated in trials as a monotherapy and in combination approaches for other solid tumours, although these potential uses remain investigational and unapproved.

来源:PharmaTimes · pharmatimes.com